A Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Subjects With Advanced Solid Cancers
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Cetrelimab (Primary) ; Erdafitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 13 Sep 2019 Planned End Date changed from 8 Jul 2021 to 17 Feb 2021.
- 13 Sep 2019 Planned primary completion date changed from 8 Jun 2021 to 8 Jun 2020.
- 20 Jun 2019 Planned number of patients changed from 30 to 21.